COMPARE 2009

NCT01016041

1 Treatments

Studied treatment  polymer based, everolimus-eluting stent (Xience V)

Control treatment  polymer-based, paclitaxel-eluting stent (Taxus Liberte)

Concomittant treatments  -

age  63.2 y

male (%)  -

Female (%)  30%

multivessel treatment  26.5%

No of stent per lesions  -

2 Patients

Patients  unselected patients

Inclusion criteria  patients aged 18–85 years; referred for elective or emergent percutaneous coronary intervention; no limitations about the number of lesions or vessels, location of lesions, or their length; life expectancy >5 years

Exclusion criteria  no dual antiplatelet therapy for 1 year; cardiogenic shock; planned major surgery within 1 month

history of MI (%)  16.5%

diabetes (%)  18%

Smoker (%)  31%

unstable angina (%)  23%

%QCA follow-up  -

QCA follow-up duration  -

3 Methods

Blinding  open
Design  Parallel groups

Centers  single centre

Geographical area  the Netherlands

Sizes  897/903

LAD (%)  38.5%

RCA (%)  33%

LCx (%)  24.5%

lesion length (mm)  16.4 mm

reference-vessel diameter  2.55 mm

lesion length inclusion criteria  -

Lesion diameter inclusion criteria  -

lesions in a bypass graft  2%

left main coronary artery disease  2%

restenotic lesion  -

totally occluded lesions  3.5%

bifurcated lesions  17.5%

ostial lesion  19%

PCI for multivessel disease  -

STEMI  25%

Stable angina  38%
## 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>target lesion failure</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MACE</td>
<td>35/897</td>
<td>57/903</td>
<td>0.62</td>
<td>[0.40; 0.95]</td>
</tr>
<tr>
<td>all cause mortality</td>
<td>18/897</td>
<td>15/903</td>
<td>1.21</td>
<td>[0.60; 2.41]</td>
</tr>
<tr>
<td>cardiac death</td>
<td>11/897</td>
<td>10/903</td>
<td>1.11</td>
<td>[0.47; 2.62]</td>
</tr>
<tr>
<td>MI</td>
<td>25/897</td>
<td>48/903</td>
<td>0.52</td>
<td>[0.32; 0.86]</td>
</tr>
<tr>
<td>Recurrent myocardial infarction</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CABG</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>angioplastie</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>target-vessel revascularization</td>
<td>19/897</td>
<td>51/903</td>
<td>0.38</td>
<td>[0.22; 0.64]</td>
</tr>
<tr>
<td>clinically driven TVR</td>
<td>19/897</td>
<td>51/903</td>
<td>0.38</td>
<td>[0.22; 0.64]</td>
</tr>
<tr>
<td>target lesion revascularisation (TLR )</td>
<td>15/897</td>
<td>43/903</td>
<td>0.35</td>
<td>[0.19; 0.64]</td>
</tr>
<tr>
<td>target vessel failure</td>
<td>56/897</td>
<td>82/903</td>
<td>0.69</td>
<td>[0.50; 0.95]</td>
</tr>
<tr>
<td>in-lesion binary restenosis</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>angiographic restenosis</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>2 yr Death (all cause)</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>2 yr MACE</td>
<td>81/897</td>
<td>124/903</td>
<td>0.66</td>
<td>[0.49; 0.88]</td>
</tr>
<tr>
<td>2 yr MI (all)</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>2 yr TLR</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>2y target lesion failure</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>4 yr mortality from all causes</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>4 yr MI</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>4 yr TLR</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>4 yr death or MI</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MACE at 5yr</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Acute stent thrombosis (&lt;=24h)</td>
<td>1/897</td>
<td>1/903</td>
<td>1.01</td>
<td>[0.06; 16.12]</td>
</tr>
<tr>
<td>sub acute stent thrombosis (1-30 days)</td>
<td>1/897</td>
<td>14/903</td>
<td>0.07</td>
<td>[0.01; 0.55]</td>
</tr>
<tr>
<td>late stent thrombosis (31d - 1year)</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stent thrombosis (ARC)</td>
<td>4/897</td>
<td>18/903</td>
<td>0.22</td>
<td>[0.08; 0.66]</td>
</tr>
<tr>
<td>Stent thrombosis (any, end of follow-up)</td>
<td>6/897</td>
<td>23/903</td>
<td>0.26</td>
<td>[0.11; 0.65]</td>
</tr>
<tr>
<td>2yr stent thrombosis</td>
<td>8/897</td>
<td>35/903</td>
<td>0.23</td>
<td>[0.11; 0.50]</td>
</tr>
<tr>
<td>4 yr stent thrombosis</td>
<td>-/897</td>
<td>-/903</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References
